跳至主要内容
临床试验/CTRI/2017/11/010539
CTRI/2017/11/010539已完成3 期

A Multi-Center, Double Blind, Randomized, Parallel-Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of Bacillus Coagulans Unique IS2 capsules in the Treatment of Functional Constipation in Adults.

nique Biotech Ltd0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Male or female subject aged between 18 and 65 years old (both inclusive).
  • 2.Has diagnosis of functional constipation according to Rome Criteria III.
  • 3.Willing to give IEC approved informed consent.
  • 4. Willing to abide by the study requirements.

排除标准

  • 1.Subjects who have undergone major abdominal surgery.
  • 2.Subjects with a documented history of slow colonic transit.
  • 3.Presence of any concomitant diseases such as organic GI diseases and/or lactose and gluten intolerance; medical or psychiatric illness
  • 4.Subjects with clinical features suggestive of alarming symptoms (rectal bleeding, weight loss, etc.)
  • 5.Family history of peptic ulcer, colorectal cancer, or IBD
  • 6.Abnormal laboratory data or thyroid function.
  • 7.Participated in any clinical trial in the past 90 days.
  • 8.Have received any probiotic formulation in the past 30 days.
  • 9.Known or expected hypersensitivity to any of the active substances or excipients.
  • 10.Subject is pregnant or lactating.
  • 11.Subject allergic or atopic to any of the ingredients of the study medication

研究者

发起方
nique Biotech Ltd

相似试验

Effect of probiotic Bacillus coagulans Unique IS2 in... | 临床试验